The fragile X syndrome, which often presents in childhood with overgrowth, may in some cases show some diagnostic overlap with classical Sotos syndrome. We describe four fragile X patients with general overgrowth, all of whom are from families with other affected relatives who show the classic Martin-Bell phenotype. Molecular studies of the FMR1 gene in all cases showed the typical full mutation as seen in males affected by the fragile X syndrome. Endocrine studies were unremarkable, except in one case where there were raised levels of insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3)
Abstract
The fragile X syndrome, which often presents in childhood with overgrowth, may in some cases show some diagnostic overlap with classical Sotos syndrome. We describe four fragile X patients with general overgrowth, all of whom are from families with other affected relatives who show the classic Martin-Bell phenotype. Molecular studies of the FMR1 gene in all cases showed the typical full mutation as seen in males affected by the fragile X syndrome. Endocrine studies were unremarkable, except in one case where there were raised levels of insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3)
These cases illustrate the clinical variability of the fragile X syndrome and the necessity of performing analysis of the FMR1 gene in mentally retarded patients presenting with general overgrowth.
(J Med Genet 1995; 32:764-769) The fragile X syndrome is the most common cause of familial mental retardation with an estimated prevalence of 1 in 1250 for males, and 1 in 2000 for females in western countries. ' 2 Identification of the FMR1 gene in 1991, and the classification of the implication of its full and premutation states, allow definite DNA molecular diagnosis in patients and carriers in nearly all cases.3 Nearly all fragile X patients show an amplification of the CGG repeat (>200) in the 5' exon of the FMR1 gene (full mutation), as compared to 6 to 54 repeats in controls and 43 to 200 CGG repeats in unaffected carriers of the premutation.
Most affected males present with the MartinBell phenotype, a combination of mental retardation, a long, large face with prominent, everted ears, and macro-orchidism.8`A phenotype less frequently observed in fragile X patients consists of extreme obesity, short stature, stubby hands and feet, and diffuse hyperpigmentation, which has been designated the Prader-Willi-like subphenotype. [12] [13] [14] In addition, a Sotos-like phenotype was reported in 1986 in two fragile X boys featuring large size at birth, unusual length, large head circumference, and minor facial anomalies. '5 Here we report clinical, endocrine, and DNA studies in four fragile X patients with overgrowth.
Patients and methods Four mentally retarded males with phenotypic features resembling Sotos syndrome were identified as fragile X positive either by cytogenetic analysis (cases 1, 3, and 4) or by gene mutation analysis (case 2) and are the subjects of this report.
DNA ANALYSIS
Genomic DNA (8 ,ug) isolated from blood leucocytes'6 was digested with the restriction enzyme HindIII according to the manufacturer's instructions, separated by gel electrophoresis, and subjected to Southern blot analysis according to standard procedures. 7 The intragenic DNA probe pP2 was used for analysis of the FMR1 gene. 18 The probe was labelled by the random oligonucleotide priming method. '9 ASSAYS OF IGF-I AND IGFBP-3 IGF-I in serum was determined by specific radioimmunoassay (RIA) after acid Sep-Pak C18 (Wares Associates, Milford, MA, USA) chromatography.20 21 IGFBP-3 levels were determined by RIA. IGFBP-3 was isolated from human plasma using the purification as modified by Martin and Baxter.22 IGFBP-3 was iodinated using the chloramine-T method (specific activity piCi/,ug). New Zealand white rabbits were immunised with 110 1ig purified . Then 0-6 ml distilled water was added and the samples were subsequently centrifuged at 10 000 g for three minutes. Pellets were washed _ t ....._ once with 0-6 ml distilled water and counted / in a z-counter (Packard Instrument Co Inc, Downers Grove, IL). The sensitivity of the assay was 0 5 ng/ml. Intra-assay variation was 6-9% at 2-52 mg/l and 12-9% at 0-83 mg/l. The interassay variation was 10-8% at 2-88 mg/l and 9-9% at 1 67 mg/l. Serum levels showed x __ parallelism with the purified human as well as recombinant glycosylated human IGFBP- This male (fig 4A, B) was born at term with a birth weight of 3125 g (25th centile). The neonatal period was uneventful. He was found to be obese at the age of 3 months with a weight of 7000 g (98th centile). His developmental milestones were moderately delayed and he was thought to have "mild non-specific mental retardation" at the age of 18 months.
At the age of 4 years 11 months his height was 121 cm (>98th centile), weight 35-8 kg (>98th centile), and head circumference 54-2 cm (>98th centile) (fig 3B, C) . He was an obese and retarded child without major abnormalities, except for a large penis with slightly enlarged testes for his age. His bone age was 51 years (7 months advanced according to the Greulich and Pyle standards). Skull x rays were normal for age and random growth hormone levels were not raised (<2 ng/ml). The diagnosis of cerebral gigantism was considered.
At the age of 18, the diagnosis of fragile X syndrome was made by cytogenetic testing (18% fragile X expression). Two male relatives (the son of the maternal grandmother's sister and the son of the sister of the maternal great grandmother) (fig 2) were also affected by the fragile X syndrome (including FMR1 gene full mutations) but showed the Martin-Bell phenotype without any symptoms of overgrowth.
At 24 years of age, height was 193 cm (>98th centile) and head circumference 61 cm (+ 4 SD). The height and head circumference of both his parents were normal, except for the father's head circumference: father's height 180 cm and head circumference 60 cm (>98th centile); mother's height 168 cm and head circumference 57 cm.
MOLECULAR AND ENDOCRINE FINDINGS
Molecular studies showed a full mutation of the FMR1 gene in all cases, with an additional premutation in cases 1 and 3 (fig 5) .
In case 1, both the insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein 3 (IGFBP-3) were raised. At the age of 2 years 9 months the IGF-1 was 138 ng/ml (> + 2 SD) and IGFBP-3 was 2-14 mg/l (> + 1 SD), at the age of 3 years 7 mnonths the IGF-I was 85 ng/ml (> + 1 SD) and IGFBP-3 was 2-52 mg/l (> + 2 SD). His thyroid function, GH, LH, FSH, and plasma testosterone levels were normal.
In case 2, the IGF-I and IGFBP-3 were both normal at the age of 3 years 4 months, 82 ng/ ml and 1 16 mg/l respectively. The phenomenon of general overgrowth prompted endocrine studies in the two younger patients. Raised IGF-I and IGFBP-3 was found in case 1, perhaps related to the extreme overgrowth. Raised IGF-I by bioassay has been found before in Sotos patients.3536 The family of IGFs and their binding proteins are involved in growth processes, including cartilage development, tissue regeneration and ovarian function.37 38 Early menopause has been reported in fragile X carriers39 and has been linked recently to the observation of increased dizygotic twinning among offspring of these carriers.40 The latter phenomenon might also be related to local IGF-I function.
The general overgrowth in the present cases might be considered as a distinct manifestation of the fragile X syndrome. Although "Sotoslike" might seem a descriptive term for this variant of the fragile X syndrome in the present cases, this term may be both confusing and lacking precision in the absence of the full characteristics of Sotos syndrome in all cases.
The fragile X syndrome is phenotypically heterogeneous with some patients showing a tendency to general overgrowth (presented here) and another minority of fragile X patients presenting with phenotypes suggesting the Prader-Willi syndrome.'1-'4 This has important implications for clinical and differential diagnosis.
In conclusion, the present four cases illustrate the clinical variability of the fragile X syndrome and the necessity of performing analysis of the FMR1 gene in mentally retarded patients presenting with general overgrowth, and in cases suspected of having Sotos syndrome.
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